Pfizer Service Agreement by cww14916


More Info
(sunitinib malate) capsules

       Access Slide Kit
Pfizer Oncology FirstRESOURCE® Program
Provides Access to Patients Seeking SUTENT

                • Coverage and reimbursement information
                  – Insurance Benefit Verification, Prior Authorization
                    Assistance, Information About Payer Policy,
                    Education About Medicare and LIS Assistance
                • Appeals assistance
                  – Assistance with appeals process with denied claims
                    or coverage
                  – Assistance with identifying sources of alternate
                  – Referrals to patient support programs
                • Patient assistance program
                  – Assists eligible underinsured and uninsured patients
                    gain access to SUTENT

                   Call FirstRESOURCE at 1-877-744-5675
                    Hours of Operation: 9am to 8pm ET
How Will Physicians and Patients Become Aware
of Services, Such as Co-Pay Assistance?

                    Refer Physicians or Patients to FirstRESOURCE,
                If They Are Concerned About Ability to Afford SUTENT

 FirstRESOURCE Will:
 — Research and Educate Patients Regarding All Available Options
   for Assistance for Patients (including All Co-Pay Foundations)
 — Directly Contact the Appropriate Foundations Based on the
   Patient’s Diagnosis and Need

 Co-Pay Assistance Organizations Will:
 — Create Awareness Through Marketing and Other Initiatives in
   an Effort to Support the Needs of Appropriate Patients

 Medicare Prescription Drug Programs
 Coverage of SUTENT
• Mandatory inclusion of drugs in 6 protected classes,
  including Oncology, is limited to treatments available in

• Medicare Prescription Drug Programs are required to
  review new agents within 90 days of availability.
   – A final formulary decision needs to be published within 180 days of availability

• Pfizer will be providing information on SUTENT to
  healthcare plans shortly after approval.

Ongoing SUTENT Studies

•   Early data suggest that SUTENT may also have activity in other tumor types. Pfizer has
    initiated an extensive clinical research program to explore the potential safety and
    efficacy of SUTENT in the treatment of a number of different types of cancer.
     – A phase III study evaluating the safety and efficacy of SUTENT as a first-line treatment for
       metastatic RCC has completed enrollment and data collection is ongoing.
     – Additional clinical studies are evaluating SUTENT as a single agent and in combination with
       other treatments for a number of other solid tumors
•   Pfizer also has a clinical trials agreement with the National Cancer Institute’s (NCI)
    Cancer Therapy Evaluation Program (CTEP) to conduct further studies of SUTENT for
    patients with many types of cancers
•   Patients and their physicians are encouraged to call the
    SUTENT clinical trial information line at 877-416-6248 or to visit the Pfizer Oncology Web
    site ( or for more information.

Please see full prescribing information

Emerging Med Trial Matching and Referral
Service Links Patients to SUTENT Clinical Trials
                                 Physician/Patient contacts
                                 Phone: (877) 416-6248

                                Patient Profile is Matched with
                                         Study Criteria

                                 Patient Selects Trial/Site

                                  Clinical Trial Specialists
                                      Provide Support:
                                  •Navigational Assistance
                                  •Ongoing Counseling


To top